Expression of serum exosomal miR‑23b‑3p in non‑small cell lung cancer and its diagnostic efficacy

Wang,Jianping; Xue,Hengchuan; Zhu,Zonghai; Gao,Jie; Zhao,Mengmeng; Ma,Zhenkai

doi:10.3892/ol.2020.11891

Expression of serum exosomal miR‑23b‑3p in non‑small cell lung cancer and its diagnostic efficacy

Authors:
- Jianping Wang
- Hengchuan Xue
- Zonghai Zhu
- Jie Gao
- Mengmeng Zhao
- Zhenkai Ma
View Affiliations

Affiliations: Department of Thoracic Surgery, People's Hospital of Yangzhong City, Yangzhong, Jiangsu 212200, P.R. China
Published online on: July 17, 2020 https://doi.org/10.3892/ol.2020.11891
Article Number: 30

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression of serum exosomal miR‑23b‑3p in non‑small cell lung cancer (NSCLC) and to determine its diagnostic efficacy for NSCLC. From October, 2017 to October, 2019, 80 patients with NSCLC, 60 patients with pneumonia and 30 healthy subjects undergoing physical examination were enrolled at the People's Hospital of Yangzhong City. Serum samples were collected from the 3 groups of patients. The expression of miR‑23b‑3p in exosomes was detected by RT‑qPCR. The Chi‑squared test was used to analyze the expression level of miR‑23b‑3p in exosomes, and the patients with NSCLC were divided into 2 groups according to the expression level. The association between the patient clinicopathological parameters and receiver operating characteristic (ROC) curves was used to evaluate the diagnostic efficacy of serum exosomal miR‑23b‑3p in NSCLC. The expression level of serum exosomal miR‑23b‑3p in the patients with NSCLC was significantly higher than that in patients with pneumonia (t=10.332, P<0.001) and healthy subjects (t=12.810, P<0.001); serum exosomal miR‑23b‑3p was significantly associated with tumor size, depth of invasion, liver metastasis and TNM stage (P<0.05). The area under the curve (AUC) for miR‑23b‑3p was 0.915 (95% CI, 0.84‑0.92), the optimal relative expression of miR‑23b‑3p was 3.46, the sensitivity of diagnosis was 87.4%, and the specificity was 93.8%, all higher than that of carcinoembryonic antigen (CEA). The ROCAUC of NSCLC was 0.645 (95% CI, 0.641‑0.772) and for Cyfra21‑1 it was 0.745 (95% CI, 0.701‑0.812). Compared with the patients with pneumonia and the healthy subjects, the patients with NSCLC exhibited a higher level of serum exosomal miR‑23b‑3p. On the whole, these findings indicate that miR‑23b‑3p has a higher clinical diagnostic efficacy and may thus be a potential biomarker for the early diagnosis of NSCLC.

View Figures

View References

1	Zhang ML, Peng P, Wu CX, Gong YM, Zhang SW, Chen WQ and Bao PP: Report of breast cancer incidence and mortality in China registry regions, 2008–2012. Zhonghua Zhong Liu Za Zhi. 41:315–320. 2019.(In Chinese). PubMed/NCBI
2	He Y, Li D, Shan B, Liang D, Shi J, Chen W and He J: Incidence and mortality of esophagus cancer in China, 2008–2012. Chin J Cancer Res. 31:426–434. 2019. View Article : Google Scholar : PubMed/NCBI
3	Caballero Vázquez A, García Flores P, Romero Ortiz A, Del Moral RG and Alcázar-Navarrete B: Changes in non-small cell lung cancer diagnosis, molecular testing and prognosis 2011–2016. J Thorac Dis. 10:5468–5475. 2018. View Article : Google Scholar : PubMed/NCBI
4	Fernandez FG, Kosinski AS, Furnary AP, Onaitis M, Kim S, Habib RH, Tong BC, Cowper P, Boffa D, Jacobs JP, et al: Differential effects of operative complications on survival after surgery for primary lung cancer. J Thorac Cardiovasc Surg. 155:1254–1264.e1. 2018. View Article : Google Scholar : PubMed/NCBI
5	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
6	Mishra S, Yadav T and Rani V: Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol. 98:12–23. 2016. View Article : Google Scholar : PubMed/NCBI
7	Chen R, Xu X, Qian Z, Zhang C, Niu Y, Wang Z, Sun J, Zhang X and Yu Y: The biological functions and clinical applications of exosomes in lung cancer. Cell Mol Life Sci. 76:4613–4633. 2019. View Article : Google Scholar : PubMed/NCBI
8	Nigita G, Distefano R, Veneziano D, Romano G, Rahman M, Wang K, Pass H, Croce CM, Acunzo M and Nana-Sinkam P: Tissue and exosomal miRNA editing in non-small cell lung cancer. Sci Rep. 8:102222018. View Article : Google Scholar : PubMed/NCBI
9	Grisard E, Coan M, Cesaratto L, Rigo I, Zandonà L, Paulitti A, Andreuzzi E, Rampioni Vinciguerra GL, Poletto E, Del Ben F, et al: Sleeping beauty genetic screen identifies miR-23b::BTBD7 gene interaction as crucial for colorectal cancer metastasis. EBioMedicine. 46:79–93. 2019. View Article : Google Scholar : PubMed/NCBI
10	Yang T, He X, Chen A, Tan K and Du X: LncRNA HOTAIR contributes to the malignancy of hepatocellular carcinoma by enhancing epithelial-mesenchymal transition via sponging miR-23b-3p from ZEB1. Gene. 670:114–122. 2018. View Article : Google Scholar : PubMed/NCBI
11	Xian X, Tang L, Wu C and Huang L: miR-23b-3p and miR-130a-5p affect cell growth, migration and invasion by targeting CB1R via the Wnt/β-catenin signaling pathway in gastric carcinoma. Onco Targets Ther. 11:7503–7512. 2018. View Article : Google Scholar : PubMed/NCBI
12	Hattori A, Takamochi K, Oh S and Suzuki K: New revisions and current issues in the eighth edition of the TNM classification for non-small cell lung cancer. Jpn J Clin Oncol. 49:3–11. 2019. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Cao M and Chen W: Epidemiology of lung cancer in China. Thorac Cancer. 10:3–7. 2019. View Article : Google Scholar : PubMed/NCBI
15	Chen W, Sun K, Zheng R, Zeng H, Zhang S, Xia C, Yang Z, Li H, Zou X and He J: Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 30:1–12. 2018. View Article : Google Scholar : PubMed/NCBI
16	Xie Y, Zhang Y, Du L, Jiang X, Yan S, Duan W, Li J, Zhan Y, Wang L, Zhang S, et al: Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer. Mol Oncol. 12:648–658. 2018. View Article : Google Scholar : PubMed/NCBI
17	Li Y, Yin Z, Fan J, Zhang S and Yang W: The roles of exosomal miRNAs and lncRNAs in lung diseases. Signal Transduct Target Ther. 4:472019. View Article : Google Scholar : PubMed/NCBI
18	Rupaimoole R, Calin GA, Lopez-Berestein G and Sood AK: miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
19	Gallach S, Jantus-Lewintre E, Calabuig-Fariñas S, Montaner D, Alonso S, Sirera R, Blasco A, Usó M, Guijarro R, Martorell M and Camps C: MicroRNA profiling associated with non-small cell lung cancer: Next generation sequencing detection, experimental validation, and prognostic value. Oncotarget. 8:56143–56157. 2017. View Article : Google Scholar : PubMed/NCBI
20	Lu S, Kong H, Hou Y, Ge D, Huang W, Ou J, Yang D, Zhang L, Wu G, Song Y, et al: Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer. Lung Cancer. 123:44–51. 2018. View Article : Google Scholar : PubMed/NCBI
21	Zaporozhchenko IA, Morozkin ES, Ponomaryova AA, Rykova EY, Cherdyntseva NV, Zheravin AA, Pashkovskaya OA, Pokushalov EA, Vlassov VV and Laktionov PP: Profiling of 179 miRNA expression in blood plasma of lung cancer patients and cancer-free individuals. Sci Rep. 8:63482018. View Article : Google Scholar : PubMed/NCBI
22	Wang P, Yang D, Zhang H, Wei X, Ma T, Cheng Z, Hong Q, Hu J, Zhuo H, Song Y, et al: Early detection of lung cancer in serum by a panel of microRNA biomarkers. Clin Lung Cancer. 16:313–319.e1. 2015. View Article : Google Scholar : PubMed/NCBI
23	Chen X, Xu Y, Liao X, Liao R, Zhang L, Niu K, Li T, Li D, Chen Z, Duan Y and Sun J: Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer. Tumour Biol. 37:11927–11936. 2016. View Article : Google Scholar : PubMed/NCBI
24	Munagala R, Aqil F and Gupta RC: Exosomal miRNAs as biomarkers of recurrent lung cancer. Tumour Biol. 37:10703–10714. 2016. View Article : Google Scholar : PubMed/NCBI
25	Zhang J, Li S, Li L, Li M, Guo C, Yao J and Mi S: Exosome and exosomal microRNA: Trafficking, sorting, and function. Genomics Proteomics Bioinformatics. 13:17–24. 2015. View Article : Google Scholar : PubMed/NCBI
26	Tang YT, Huang YY, Zheng L, Qin SH, Xu XP, An TX, Xu Y, Wu YS, Hu XM, Ping BH and Wang Q: Comparison of isolation methods of exosomes and exosomal RNA from cell culture medium and serum. Int J Mol Med. 40:834–844. 2017. View Article : Google Scholar : PubMed/NCBI
27	Jiang ZF, Wang M and Xu JL: Thymidine kinase 1 combined with CEA, Cyfra21-1 and NSE improved its diagnostic value for lung cancer. Life Sci. 194:1–6. 2018. View Article : Google Scholar : PubMed/NCBI
28	Begum S, Hayashi M, Ogawa T, Jabboure FJ, Brait M, Izumchenko E, Tabak S, Ahrendt SA, Westra WH, Koch W, et al: An integrated genome-wide approach to discover deregulated microRNAs in non-small cell lung cancer: Clinical significance of miR-23b-3p deregulation. Sci Rep. 5:132362015. View Article : Google Scholar : PubMed/NCBI
29	Chen D, Wu X, Xia M, Wu F, Ding J, Jiao Y, Zhan Q and An F: Upregulated exosomic miR-23b-3p plays regulatory roles in the progression of pancreatic cancer. Oncol Rep. 38:2182–2188. 2017. View Article : Google Scholar : PubMed/NCBI
30	Wei DM, Dang YW, Feng ZB, Liang L, Zhang L, Tang RX, Chen ZM, Yu Q, Wei YC, Luo DZ and Chen G: Biological effect and mechanism of the miR-23b-3p/ANXA2 axis in pancreatic ductal adenocarcinoma. Cell Physiol Biochem. 50:823–840. 2018. View Article : Google Scholar : PubMed/NCBI